Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$141.98 - $304.39
Previous CloseN/A
Volume78.96K
Average Volume (3M)805.70K
Market Cap
$32.98B
Enterprise Value$35.31B
Total Cash (Recent Filing)$966.43M
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 01, 2025EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding130,074,000
10 Day Avg. Volume911,486
30 Day Avg. Volume805,696
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14.60
Price to Cash Flow (P/CF)-86.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.35
Enterprise Value/Ebitda-182.95
Forecast
1Y Price Target
$318.71Price Target Upside12.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Bulls Say, Bears Say
Bulls Say
Commercial PositioningThe label outcome is viewed as a bull case for Alnylam on both commercial positioning and reimbursement fronts.
FDA ApprovalThe FDA approval of AMVUTTRA for ATTR amyloidosis with cardiomyopathy marks a key inflection point for Alnylam's long-term growth targets.
Market ExpansionThe company expects the market for their drug to expand significantly over time, with a large percentage of patients still undiagnosed.
Bears Say
Market Share ExpectationsMarket share assumptions have been moderated in the near term, with decreased peak share assumptions in both the US and EU markets.
Pricing PressuresIn the EU, the assumption of annual price decreases has been increased from 1% to 2%, reflecting potential pricing pressures.
Pricing StrategyThe company plans to reduce the net price of Amvuttra over time with volume-based rebates.
---
Ownership Overview
0.38% Insiders
49.21% Mutual Funds
0.14% Other Institutional Investors
35.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $141.97 and its highest was $304.39 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $32.98B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 39 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 13, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.592 by -$0.058.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -0.93.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 130,074,000 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.592. Following the earnings report the stock price went down -0.402%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$318.71 (12.48% Upside)
$318.71 (12.48% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 96.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
93.24%
12-Months-Change
Fundamentals
Return on Equity
-414.62%
Trailing 12-Months
Asset Growth
12.32%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company that focuses on the development and commercialization of RNA interference (RNAi) therapeutics. These therapeutics are designed to silence specific messenger RNAs, thereby inhibiting the expression of disease-causing proteins. Alnylam's core products target rare genetic diseases, and the company is a leader in the field of RNAi technology, with a pipeline that includes treatments for conditions such as hereditary ATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1.
---
ALNY Company Deck
---
ALNY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant revenue growth, profitability, and progress in clinical trials. Despite a slight decline in the rare franchise and anticipated decrease in gross margins, the strong performance and guidance in key areas like the TTR franchise and R&D pipeline suggest a positive outlook.Read More>---
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
ALNY Stock 12 Month Forecast
Average Price Target
$318.71
▲(12.48% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Biogen
―
Ionis Pharmaceuticals
―
Vertex Pharmaceuticals
―
Sarepta Therapeutics
―
Best Analysts Covering ALNY
1 Year
1 Year Success Rate
26/30 ratings generated profit
1 Year Average Return
+31.74%
reiterated a buy rating 3 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +31.74% per trade.
---